Yuan Liu

Dr. Yuan Liu


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2019 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
YLYuan Liu
Yuan Liu
ZZZiying Zou
Ziying Zou
ZHZonghai Hu
Zonghai Hu
WWWenbo Wang
Wenbo Wang
JXJie Xiong
Jie Xiong
Objective: To identify the pathogen causing fungemia in a Chinese patient and describe its morphological and molecular characterizes. Methods: Samples of central and peripheral venous blood were collected for blood culture. Morphology and drug sensitivities of the isolated yeast-like fungus were analyzed. rDNA sequencing and molecular phylogenetic analysis of the isolated strains were performed using DNAMAN and MEGA software. Results: A strain of yeast-like fungi was repeatedly isolated from blood samples of a Chinese patient. The isolates grew well on sabouraud medium broth plate. The colonies were smooth and round at 28∘C, and were of rough surface and irregular shape at 35∘C. Molecular phylogenetic trees constructed based on the internal transcribed spacer (ITS) and D1/D2 domains of 28S rDNA gene demonstrated the isolated yeast-like fungus was Moesziomyces antarcticus. Drug susceptibility test showed that this isolated M. antarcticus was resistant or had relatively low susceptibility to flucytosine, fluconazole, voriconazole, and itraconazole, and only sensitive to amphotericin. Conclusion: This study provided more information for the molecular and morphology characteristics of M. antarcticus and reviewed the species information of Moesziomyces associated with human infections, which will contribute to the identification and diagnosis of Moesziomyces infections.

19 February 2016 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
YLYuan Liu
Yuan Liu
LCLi Chen
Li Chen
ZZZiying Zou
Ziying Zou
BZBing Zhu
Bing Zhu
ZHZonghai Hu
Zonghai Hu
JXJie Xiong
Jie Xiong

10 December 2018 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
YLYuan Liu
Yuan Liu
WWWenbo Wang
Wenbo Wang
ZZZiying Zou
Ziying Zou
ZHZonghai Hu
Zonghai Hu
QFQuanshui Fan
Quanshui Fan
JXJie Xiong
Jie Xiong

8 April 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
WSWei Sun
Wei Sun
YJYang Jian
Yang Jian
XFXiaolin Feng
Xiaolin Feng
MZMinru Zhao
Minru Zhao
YLYuan Liu
Yuan Liu
Objective: Chemotherapy-induced oral mucositis (CTOM) is a common side effect affecting 20%–40% of cancer patients receiving chemotherapy. Kangfuxin liquid (KFXL) has been used clinically to prevent and treat CTOM, but the evidence has not been systematically evaluated. This study aimed to evaluate the preventive and therapeutic effects of KFXL on CTOM.Methods: Nine electronic databases were searched to identify KFXL-related randomized controlled trials (RCTs) for the prevention and treatment of CTOM from inception to September 2024. The primary outcomes were incidence rate, efficacy rate and cure rate, and the secondary outcomes was healing time.Results: Twenty-one trials involving 1825 patients were included in this review. The results of our meta-analysis showed that, compared with basic oral care (BOC), KFXL significantly reduced the incidence rate of CTOM and severe CTOM (RR = 0.54, p < 0.00001; RR = 0.23, p < 0.00001, respectively), improved the efficacy rate of CTOM and severe CTOM (RR = 1.23, p = 0.0003; RR = 1.99, p = 0.05, respectively), improved the cure rate of CTOM (RR = 2.06, p = 0.0004),and accelerated the healing process (MD = −2.48, p < 0.00001). However, KFXL and other drugs have the same efficacy rate in treating CTOM and severe CTOM (RR = 1.00, p = 0.99; RR = 1.00, p = 1.00, respectively), and the same cure rate in CTOM (RR = 0.91, p = 0.39), and the same healing time (MD = −0.01, p = 1.00).Conclusion: The results suggest that KFXL may provide more benefit in the prevention and treatment for CTOM compared to BOC. Although KFXL may be a promising drug for the prevention and treatment of CTOM, the evidence is insufficient to prove its superiority over other guideline-recommended treatment.Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024585859, ID: CRD42024585859.

Verified
Journal Article
Open access
PDF file
YLYuan Liu
Yuan Liu
ZZZiying Zou
Ziying Zou
BZBing Zhu
Bing Zhu
ZHZonghai Hu
Zonghai Hu
PZPing Zeng
Ping Zeng
Golgi protein 73 (GP73), which is up-regulated in hepatocellular carcinoma (HCC), has recently been identified as a novel serum marker for HCC diagnosis. Several reports also noted the increased levels of GP73 expression in chronic liver disease in patients with acute hepatitis of various etiologies, chronic Hepatitis C virus (HCV) infection and alcoholic liver disease. The molecular mechanisms of GP73 expression in HCV related liver disease still need to be determined. In this study, we aimed to evaluate the effect of HCV infection on GP73 expression. GP73 was highly expressed in Huh7, Hep3B, 293T and HUVEC cells, and was low-expressed in HepG2 cells. HCV infection led to down-regulation of GP73 in Huh7 and HepG2/CD81 cells at the early stage of infection. CXCL10 decreased GP73 expression in Huh7 and HepG2 cells. Up-regulation of GP73 was noted in hepatocytes with cytopathic effect at advanced stage of HCV infection, and further research is needed to determine the unknown factors affecting GP73 expression. In conclusion, our study provided additional evidence for the roles of GP73 in liver disease.

23 May 2015 in Hepatitis Monthly
Verified
Journal Article
Open access
PDF file
YLYuan Liu
Yuan Liu
ZZZiying Zou
Ziying Zou
BZBing Zhu
Bing Zhu
ZHZonghai Hu
Zonghai Hu
PZPing Zeng
Ping Zeng
LWLijuan Wu
Lijuan Wu
Background: Hepatitis C virus infection is one of the leading causes of end stage liver diseases. The innate immune response slows down viral replication by activating cytokines such as type I interferon (IFN-α/β), which trigger the synthesis of antiviral proteins and modulate the adaptive immune system. Recently, leucine-rich repeat (in Flightless I) interacting protein-1 (LRRFIP1) was reported contributing to the production of interferon-β in macrophages. Objectives: The aim of this study was to assess the role of LRRFIP1 in induction of IFN-β and inhibition of HCV infection in hepatocytes. Materials and Methods: Induction of IFN-β by LRRFIP1 in Huh7 and Huh7.5.1 was determined by real-time PCR and western blotting in vitro. Inhibition of HCV replication by LRRFIP1 overexpression in hepatocytes was assessed. Results: LRRFIP1 increased the expression of IFN-β in hepatocytes with or without HCV infection. Induction of IFN-β by LRRFIP1 was enhanced with the presence of hepatitis C virus. Overexpression of LRRFIP1 in hepatocytes inhibited HCV replication. However, HCV infection did not regulate intracellular expression of LRRFIP1. Conclusions: LRRFIP1 and its mediated production of type I interferon play a role in controlling HCV infection. The findings of this study provide new target for HCV treatment and contribute to development of anti-HCV drugs. Keywords: LRRFIP1 Protein, Human; Hepacivirus; Interferon Type I